Warning letter
Noven Pharmaceuticals, Inc. [ARCHIVED]: warning letter of Aug 25, 2011
FDA warning letter 173292 · Los Angeles District Office
Key facts
| Reference number | 173292 |
|---|---|
| Company | Noven Pharmaceuticals, Inc. [ARCHIVED] |
| Subject | CGMP for Finished Pharmaceuticals/Adulterated |
| Issue date | Aug 25, 2011 |
| Posted date | Aug 25, 2011 |
| Issuing office | Los Angeles District Office |
| Product type | Drugs |
| CFR sections cited | 211.103, 211.192, 211.68(a), 211.68(b), 211.100(a) |
| Inspection city | Carlsbad |
| Inspection ZIP | 92010 |
| Inspection start date | Jan 31, 2011 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: